Medistim ASA has transferred 10 000 shares to CEO Kari Krogstad's 100% owned
company K2 Consulting. This is according to the agreement entered between
Medistim ASA and the CEO under the same terms as described in the annual report.
The shares have a lock up period of 3 years and this qualifies for a discount.
The shares were therefore purchased at 161,44 per share. To finance the
purchase, Medistim has given the CEO a loan and when the lock in period has
ended, she is given a bonus equal to the loan amount. K2 Consulting AS has in
total 44.500 shares after the purchase. After these transactions Kari E.
Krogstad controls in total 90.583 Medistim shares. Medistim ASA has 44.487 own
shares after the transactions.